Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. - Wikidata - awgldk - TriplyDB

Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome.

Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome.

http://www.wikidata.org/entity/Q44183283

about

Autoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunity Pathophysiology and Treatments of Oxidative Injury in Ischemic Stroke: Focus on the Phagocytic NADPH Oxidase 2 Anti-Apolipoprotein A-1 IgG Predict All-Cause Mortality and Are Associated with Fc Receptor-Like 3 Polymorphisms.Evaluation of serum paraoxonase and arylesterase activities in ankylosing spondylitis patients Autoimmune-mediated reduction of high-density lipoprotein-cholesterol and paraoxonase 1 activity in systemic lupus erythematosus-prone gld mice.The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus.Could antibodies to C-reactive protein link inflammation and cardiovascular disease in patients with systemic lupus erythematosus?SLE, atherosclerosis and cardiovascular disease.Cardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry.Nonorgan specific autoantibodies and heart damage.Antiphospholipid antibodies are associated with enhanced oxidative stress, decreased plasma nitric oxide and paraoxonase activity in an experimental mouse model Anti-apolipoprotein A-I antibodies and paraoxonase 1 activity in Systemic Lupus Erythematosus Autoantibodies to apolipoprotein A-1 in cardiovascular diseases: current perspectives.Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus.Accelerated atherosclerosis is independent of feeding high fat diet in systemic lupus erythematosus-susceptible LDLr(-/-) mice.Systemic lupus erythematosus and cardiovascular disease.The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus.Autoimmune-mediated atherothrombosis.Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus.Mitochondrial Dysfunction in the Liver and Antiphospholipid Antibody Production Precede Disease Onset and Respond to Rapamycin in Lupus-Prone Mice.Association between serum total antioxidant status and flow-mediated dilation in patients with systemic lupus erythematosus: an observational study The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus?The clinical significance of posttranslational modification of autoantigens.Pathogenesis and treatment of atherosclerosis in lupus.Biomarkers for cardiovascular risk assessment in autoimmune diseases.Extended-release niacin increases anti-apolipoprotein A-I antibodies that block the antioxidant effect of high-density lipoprotein-cholesterol: the EXPLORE clinical trial.ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease.Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events.Enhanced reactivity to malondialdehyde-modified proteins by systemic lupus erythematosus autoantibodies.High-density lipoprotein inversely relates to its specific autoantibody favoring oxidation in thrombotic primary antiphospholipid syndrome.The prevalence of dyslipoproteinemia in Thai patients with systemic lupus erythematosus.High-density lipoproteins are abnormal in young women with uncomplicated systemic lupus erythematosus.Genetic variation in the paraoxonase-3 (PON3) gene is associated with serum PON1 activity.Antibodies toward high-density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus.Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus.Review: Metabolic Control of Immune System Activation in Rheumatic Diseases.Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome patients.Immune-Mediated Heart Disease.Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus.

P2860

Q27004493-796EE210-9D72-4A1F-94F5-0EA4BCF27CEB Q27005956-310A9266-1E82-4A46-80F6-D37F2D08B1F0 Q33573479-358B8352-2CAD-4D84-96FE-031FC7987BF5 Q33684694-31078562-283E-4678-8885-77B26F610043 Q34546651-C8570522-034B-4AF8-B45A-20372A7050CC Q35169351-47B705ED-494D-48EE-B953-BF86D16EE34F Q35953555-0012CE86-E6B2-45D0-A4A1-569E8DD2799D Q36135534-D891AACB-5AAB-49F1-BA34-FA3457BD47E3 Q36153524-BFE3636E-EC47-4E5C-97A5-6BC67B05E5AC Q36283415-0E50D18E-3B61-46C1-973D-F19F22C73511 Q36300619-8EE8D7AE-E215-4F6A-A79D-DE532FC0A11C Q36330112-0229D582-A780-458D-BBD8-C65F6BDD9EFB Q36438919-C89E578B-01C9-4C51-B91D-82DEB3B561EE Q36596375-02D977FB-5149-49E1-B1B7-C4E18DB34FD0 Q37143021-EBAE0545-F3E3-4A05-8E2E-64FA156D6315 Q37167995-F5AE4D72-93A5-41DB-A076-365F19281569 Q37206876-EC4B3C38-B03E-4EC7-A959-C3117162E56D Q37283009-5A24E2BE-6F12-4038-804F-98022682EA93 Q37367326-14EDFFB5-972F-4909-97A9-8AE880FE35C7 Q37372436-DFC21CA2-F69B-4CA5-ADAC-D849733CA24D Q37680541-66B2E7E9-C3B7-4085-ABF0-35344BDBDA59 Q37817582-4ECCFDE8-B1D7-4276-9A86-397771870492 Q38212757-678E2CEC-9A43-476D-A90C-AADAE03297B7 Q38230699-0C7BC8F2-C273-42AC-8F09-A576B1CF3234 Q38293735-3D12B3FB-EB7A-4E45-8FCB-1FFBC3846869 Q38384208-C01869C0-250C-4D70-AFE0-CC9C684D9709 Q38835289-A11BD044-EB81-4233-8AAB-725BD5EF70D2 Q39150632-6520DB9F-3662-4F0A-8DDC-E3622D2D074D Q40461525-F891B1A7-07D2-4EA4-A028-F6E5BD7D701D Q43080330-8FBFBD6E-37B1-4C67-992E-ADDACDAA46E6 Q43197413-A6DAFDD9-4792-4DA4-819E-635C0A5A02BF Q45220920-D4537575-60AB-44CA-BF48-BF66E132A983 Q46318778-A2270009-5EB3-4BB0-89CC-21CB71993F44 Q46978184-1845BB03-F8D2-4069-AE1E-5FD490A88E2A Q46982870-C283B15C-9EA9-4C2E-9A6F-86BF90CC6A59 Q46982878-1214D678-009A-45AD-AEE4-2251EB1C01D1 Q47133379-6DE869BC-0992-4EAE-90E8-58A9CF9325E4 Q51550154-C3132236-46FE-484D-A14C-2821406E315D Q51835838-63184B8C-144E-4EB9-A2FC-24854E667B8E Q52316454-847A6A79-6A5E-4208-A43E-25ACA925FECC

P2860

Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome.

http://www.wikidata.org/entity/Q44183283

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Antibodies to high-density lip ...... ary antiphospholipid syndrome.

@en

Antibodies to high-density lip ...... ary antiphospholipid syndrome.

@nl

type

label

Antibodies to high-density lip ...... ary antiphospholipid syndrome.

@en

Antibodies to high-density lip ...... ary antiphospholipid syndrome.

@nl

prefLabel

Antibodies to high-density lip ...... ary antiphospholipid syndrome.

@en

Antibodies to high-density lip ...... ary antiphospholipid syndrome.

@nl

P1433

Q44183283-548BB7FE-9033-4717-AF81-42F5CCD75169

P1476

Q44183283-1B1A4E65-E901-49C0-A8B3-CE126D90A21E

P2093

Q44183283-018A5E41-2626-4A8E-A32B-D41DB329D430

Q44183283-57AEA5EE-9042-4396-B4D8-32B79669C32D

Q44183283-8BE34F4B-F021-4980-863A-B45FD9C3E0CD

Q44183283-8C102F64-2DC2-417A-ABA0-BF740D718598

Q44183283-AF41EAE7-0C67-4AB3-A566-27FEA31BD4D6

Q44183283-C8BAC6E3-F1BB-4DDD-A42E-4F4C2FCD6474

P2860

Q44183283-0359ABA4-0EDA-4A27-AA07-907DBF30B6B1

Q44183283-07055B92-23C2-4B7B-9F36-5E94E1EC93E8

Q44183283-094A2F74-EA86-4C34-8395-68D70F3392B4

Q44183283-09BFAB32-8D26-4B4C-B1CF-21C2B702EDB9

Q44183283-1E0A46EA-1859-426A-8A7D-97D8AAE5352A

Q44183283-2118C650-6D36-470B-90C4-F47539556398

Q44183283-29416741-CE53-44CB-B4EE-26D8FF8D861B

Q44183283-36ED92C7-39F6-48B7-A524-CB6D0DDAB992

Q44183283-51574B34-EDBB-4129-91CD-0DBE3FD769A2

Q44183283-59FB0099-BE76-4093-A613-0A2EB5B30E8C

P304

Q44183283-350495A5-DABC-4925-A467-5819BB5D138E

P31

Q44183283-F0F214E6-B737-4B81-8EB1-14D7E390B137

P356

Q44183283-F0BCED34-1169-4BB8-8F00-3A93C0463ED4

P433

Q44183283-BEFC8E8F-4065-479E-A83D-813028C9BFD4

P478

Q44183283-5E416F68-D9FE-4FAE-80F5-9088230B87AA

P50

Q44183283-78FB0A55-58F4-42B9-AC73-985E9164460C

P577

Q44183283-B9BD9B37-366C-4E8D-9F38-DC07192353BE

P5875

Q44183283-8C481FAB-3828-41D3-8242-00815AA6F7FA

P698

Q44183283-2D497FF7-A6F4-4DDD-AF80-F03B0DD54D28

P921

Q44183283-0DF26499-C414-4E2C-85AE-9ECF3BE63CCB

Q44183283-D5B2DB97-FBAC-48E2-B051-1F29FB136D9C

P356

P1433

Arthritis & Rheumatology

P1476

Antibodies to high-density lip ...... ary antiphospholipid syndrome.

@en

P2093

Ames PR

http://www.w3.org/2001/XMLSchema#string

Delgado Alves J

http://www.w3.org/2001/XMLSchema#string

Donohue S

http://www.w3.org/2001/XMLSchema#string

Nourooz-Zadeh J

http://www.w3.org/2001/XMLSchema#string

Ravirajan C

http://www.w3.org/2001/XMLSchema#string

Stanyer L

http://www.w3.org/2001/XMLSchema#string

P2860

Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity

Atherosclerosis — An Inflammatory Disease

Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus

Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus

Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I

The 1982 revised criteria for the classification of systemic lupus erythematosus

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

Anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome recognize epitopes in both beta(2)-glycoprotein 1 and oxidized low-density lipoprotein.

International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.

Antibodies to oxidised LDL.

P304

2686-2694

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.10542

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

David A. Isenberg

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11076200

http://www.w3.org/2001/XMLSchema#string

P698

12384928

http://www.w3.org/2001/XMLSchema#string

P921